EUVIMEDEUVIMED entdecken
Klinische Studie

Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – 12-month data from an open-label pilot study

Sara Ellis, Catherine Bostian, Anna Donnelly, Wendy Feng, Katherine Eisen, Melanie Lean, Elizabeth Conlan, Michael Ostacher, Scott Aaronson, Trisha Suppes

Journal of Affective Disorders · 2025-11 · 389 · 119655

DOI: 10.1016/j.jad.2025.119655 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Affective Disorders, 2025-11. Verfasst von Sara Ellis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, Ohio State University, Columbus, OH, USA. Hauptthemen laut MEDLINE: Psilocybin, Veterans, Depressive Disorder, Treatment-Resistant, Major Depressive Disorder. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Sage Therapeutics, Compass Pathways.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: One-third of Veterans with major depressive disorder suffer from treatment-resistant depression (TRD). This is the first study to evaluate the long-term outcomes of psilocybin in Veterans with severe TRD. METHODS: This paper presents 12-month results from an open-label pilot study assessing the effects of 25 mg psilocybin in Veterans with severe TRD, defined as a major depressive episode failing to respond to ≥5 treatments, or lasting >2 years. 10 out of 15 participants completed the 12-month follow-up. Depression severity was measured by Montgomery-Åsberg Depression Rating scale (MADRS) at 6, 9, and 12 months posttreatment. Response was defined as ≥50 % reduction in MADRS, and remission as ≤10 MADRS score. RESULTS: Depression scores show significant reductions from Baseline across all timepoints. However, there was an increase in MADRS scores from short-term timepoints (Weeks 3 and 12) to Month 12. Of 10 participants, at Month 6, 80 % met response and 50 % met remission criteria for the MADRS. At Month 9, acute responses began to wane. At Month 12, 40 % maintained response and 30 % maintained remission. LIMITATIONS: Limitations include the small sample size and the uncontrolled, unblinded design. CONCLUSIONS: In this first-of-kind study on long-term effects of psilocybin for Veterans with severe TRD, depression scores showed significant sustained reductions up to 12-months. However, the antidepressant effects began to wane at 6 months, and then more substantially after 9 months, although these increases in MADRS did not reach statistical significance. Further research is needed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04433858.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsilocybinVeteransDepressive Disorder, Treatment-ResistantMajor Depressive DisorderHallucinogensHumansPilot ProjectsMaleMiddle AgedAdultFemaleTreatment OutcomeUnited StatesPsychiatric Status Rating ScalesFollow-Up Studies

Stichwörter der Autor:innen

DepressionLong-term outcomesPsilocybinPsychedelicsTreatment-resistant depressionVeterans

Substanzen

PsilocybinHallucinogens

Autor:innen und Institutionen

  • Department of Psychology, Ohio State University, Columbus, OH, USA.
  • VA Palo Alto Health Care System, Palo Alto, CA, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
  • VA Palo Alto Health Care System, Palo Alto, CA, USA.
  • Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
  • Institute for Advanced Diagnostics and Treatment, Sheppard Pratt Health System, Baltimore, MD, USA.
  • VA Palo Alto Health Care System, Palo Alto, CA, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA. Electronic address: tsuppes@stanford.edu.

Förderung

  • Sage Therapeutics
  • Compass Pathways

Zitieren

APA

Ellis, S., Bostian, C., Donnelly, A., Feng, W., Eisen, K., Lean, M., Conlan, E., Ostacher, M., Aaronson, S., & Suppes, T. (2025). Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – 12-month data from an open-label pilot study. Journal of Affective Disorders, 389, 119655. https://doi.org/10.1016/j.jad.2025.119655

Vancouver

Ellis S, Bostian C, Donnelly A, Feng W, Eisen K, Lean M, et al. Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – 12-month data from an open-label pilot study. Journal of Affective Disorders. 2025;389:119655. doi:10.1016/j.jad.2025.119655

BibTeX
@article{Ellis2025,
  author = {Ellis, Sara and Bostian, Catherine and Donnelly, Anna and Feng, Wendy and Eisen, Katherine and Lean, Melanie and Conlan, Elizabeth and Ostacher, Michael and Aaronson, Scott and Suppes, Trisha},
  title = {Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – 12-month data from an open-label pilot study},
  journal = {Journal of Affective Disorders},
  year = {2025},
  volume = {389},
  pages = {119655},
  doi = {10.1016/j.jad.2025.119655}
}
Kostenlos starten →